This company has been acquired
Resumen acción AGTC
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de Applied Genetic Technologies Corporation
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.39 |
| 52 Week High | US$2.83 |
| 52 Week Low | US$0.23 |
| Beta | 1.58 |
| 1 Month Change | -4.23% |
| 3 Month Change | -1.85% |
| 1 Year Change | -80.89% |
| 3 Year Change | -86.79% |
| 5 Year Change | -89.78% |
| Change since IPO | -97.33% |
Noticias y actualizaciones recientes
Recent updates
AGTC receives positive feedback from FDA for manufacturing facility
Jul 26Applied Genetic Technologies proposes stock offering to fund clinical trials
Jul 12Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022
Jan 12An Assessment Of Applied Genetic Technologies Corporation
Dec 14Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Jul 15Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?
May 21
Applied Genetic trades lower after announcing the departure of chief scientific officer
Apr 26What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?
Feb 05
Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?
Jan 06What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Dec 11Interim data on gene therapy for vision loss disorder fails to lift Applied Genetic
Nov 11Rentabilidad de los accionistas
| AGTC | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 4.8% | -2.8% | -1.7% |
| 1Y | -80.9% | -0.2% | 22.4% |
Rentabilidad vs. Industria: AGTC underperformed the US Biotechs industry which returned -10.2% over the past year.
Rentabilidad vs. Mercado: AGTC underperformed the US Market which returned -14.8% over the past year.
Volatilidad de los precios
| AGTC volatility | |
|---|---|
| AGTC Average Weekly Movement | 19.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: AGTC's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: AGTC's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1999 | 102 | Sue Washer | agtc.com |
Resumen de fundamentos de Applied Genetic Technologies Corporation
| Estadísticas fundamentales de AGTC | |
|---|---|
| Capitalización bursátil | US$12.62m |
| Beneficios(TTM) | -US$70.23m |
| Ingresos (TTM) | US$325.00k |
38.9x
Ratio precio-ventas (PS)-0.2x
Ratio precio-beneficio (PE)¿Está AGTC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de AGTC | |
|---|---|
| Ingresos | US$325.00k |
| Coste de los ingresos | US$21.76m |
| Beneficio bruto | -US$21.44m |
| Otros gastos | US$48.80m |
| Beneficios | -US$70.23m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.19 |
| Margen bruto | -6,596.62% |
| Margen de beneficio neto | -21,610.46% |
| Ratio deuda/patrimonio | 92.6% |
¿Cómo se ha desempeñado AGTC a largo plazo?
Ver rendimiento histórico y comparativa